

Camden and Islington NHS Foundation Trust  
3rd Floor, Room 3/25, West Wing  
St Pancras Hospital  
4 St Pancras Way  
London  
NW1 0PE

E-mail: [Freedom.Information@Candi.nhs.uk](mailto:Freedom.Information@Candi.nhs.uk)  
[cim-tr.information-request@nhs.net](mailto:cim-tr.information-request@nhs.net)  
Online: [www.candi.nhs.uk](http://www.candi.nhs.uk)  
Telephone: +44(0)20 3317 7100

**Reference number:** FOI 2022-90

Oliver Caswell  
[request-875789-14d55ca1@whatdotheyknow.com](mailto:request-875789-14d55ca1@whatdotheyknow.com)

07 July 2022

Dear Oliver Caswell,

### **Freedom of Information Request**

Thank you for your information request which we received on **5<sup>th</sup> July 2022**. In line with the Freedom of Information Act 2000 (FOIA), Camden and Islington NHS Foundation Trust (C&I NHS FT) is pleased to respond as below.

### **Your request and our response:**

- 1) In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?

**This is not applicable to our Trust as we are Adult Mental Health Trust and therefore do not treat patients for any of the above diseases**

- 2) Of these five, how many of each received the following products:

- Adalimumab (Humira)
- Adalimumab Biosimilar
- Etanercept (Enbrel)
- Etanercept Biosimilar
- Infliximab (Remicade)
- Infliximab biosimilar
- Golimumab (Simponi)
- Tofacitinib (Xeljanz)

- Ustekinumab (Stelara)
- Vedolizumab (Entyvio)
- Filgotinib (Jyseleca)
- Abatacept (Orencia)
- Baricitinib (Olumiant)
- Certolizumab Pegol (Cimzia)
- Rituximab (MabThera)
- Rituximab Biosimilar
- Tocilizumab (RoActemra)
- Sarilumab (Kevzara)
- Apremilast (Otezla)
- Secukinumab (Cosentyx)
- Isekizumab (Taltz)
- Guselkumab (Tremfya)
- Brodalumab (Kyntheum)
- Risankizumab (Skyrizi)
- Tildrakizumab (Ilumetri)
- Upadacitinib (Rinvoq)
- Bimekizumab (Bimzelx)

**N/A – please see response to question 1**

- 3) Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).

**N/A – we do not have a gastro department**

- 4) Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?

- AxSPA
- PsA
- PsO

**N/A – please see response to question 1**

## **Review**

We hope you are satisfied with the way in which your request was handled, if not you may request an internal review at the above email address within 28 days of this letter. When contacting the Trust please use the above reference that is unique to your request.

If you remain dissatisfied with the outcome of the internal review, you may seek further recourse by lodging an appeal with the Information Commissioner's Office (ICO) at Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF or on the ICO's website via the following link:

<https://ico.org.uk/global/contact-us/>

Yours sincerely,

## Information Governance Team



WE: VALUE EACH OTHER, ARE EMPOWERED, KEEP THINGS SIMPLE, ARE CONNECTED